Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice

Journal of Immunology

Volumn 180, Issue 10, 2008, Pages 6954-6961

  Riad, Alexander ^a   Jäger, Sebastian ^a   Sobirey, Meike ^a   Escher, Felicitas ^a   Yaulema Riss, Aymaru ^a   Westermann, Dirk ^a   Karatas, Aysun ^b   Heimesaat, Markus M ^a   Bereswill, Stefan ^a   Dragun, Duska ^b   Pauschinger, Matthias ^a   Schultheiss, Heinz P ^a   Tschöpe, Carsten ^a,c  

^a Campus Benjamin ^*  (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; COLLAGEN; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE C DELTA; PROTEIN P42; PROTEIN P44; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 4; CALCINEURIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; C57BL 10 MOUSE; CONTROLLED STUDY; CORRELATION ANALYSIS; HEART INFARCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL; WILD TYPE; ANIMAL; GENE EXPRESSION; GENETICS; HEART VENTRICLE REMODELING; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NICK END LABELING; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; WESTERN BLOTTING;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOTTING, WESTERN; CALCINEURIN; COLLAGEN; GENE EXPRESSION; IN SITU NICK-END LABELING; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYELOID DIFFERENTIATION FACTOR 88; MYOCARDIAL INFARCTION; PROTEIN KINASE C-DELTA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 4; VENTRICULAR REMODELING;

EID: 45549084247     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.10.6954     Document Type: Article

References (51)

1. Lewis, E. F., L. A. Moye, J. L. Rouleau, F. M. Sacks, J. M. Arnold, J. W. Warnica, G. C. Flaker, E. Braunwald, and M. A. Pfeffer. 2003. Predictors of lale development of heart failure in stable survivors of myocardial infarction: the CARE study. J. Am. Coll. Cardiol. 42: 1446-1453.
2. Opie, L. H., P. J. Commerford, B. J. Gersh, and M. A. Pfeffer. 2006. Controversies in ventricular remodelling. Lancet 367: 356-367.
3. Liao, Y. H., and X. Cheng. 2006. Autoimmunity in myocardial infarction. Int. J. Cardiol. 112:21-26.
4. Frangogiannis, N. G. 2006. Targeting the inflammatory response in healing myocardial infarcts. Curr. Med. Client. 13: 1877-1893.
5. Fan, J., Y. Li, R. M. Levy, J. J. Fan, D. J. Hackam, Y. Vodovotz, H. Yang, K. J. Tracey, T. R. Billiar, and M. A. Wilson. 2007. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J. Immunol. 178: 6573-6580.
6. Frisancho-Kiss, S., S. E. Davis, J. F. Nyland, J. A. Frisancho, D. Cihakova, M. A. Barrett, N. R. Rose, and D. Fairweather. 2007. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J. Immunol. 178: 6710-6714.
7. Nozaki, N., T. Shishido, Y. Takeishi, and I. Kubota. 2004. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 110:2869-2874.
8. Shishido, T., N. Nozaki, S. Yamaguchi, Y. Shibata, J. Nitobe, T. Miyamoto, H. Takahashi, T. Arimoto, K. Maeda, M. Yamakawa, et al. 2003. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 108: 2905-2910.
9. Oyama, J., C. Blais, Jr., X. Liu, M. Pu, L. Kobzik, R. A. Kelly, and T. Bourcier. 2004. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109: 784-789.
10. Smiley, S. T., J. A. King, and W. W. Hancock. 2001. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J. Immunol. 167: 2887-2894.
11. * Trial). Am. J. Cardiol. 92: 152-160.
12. Ohashi, K., V. Burkart, S. Flohe, and H. Kolb. 2000. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J. Immunol. 164: 558-561.
13. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4:499-511.
14. Heineke, J., and J. D. Molkentin. 2006. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7: 589-600.
15. Boyd, J. H., S. Mathur, Y. Wang, R. M. Bateman, and K. R. Walley. 2006. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-κB dependent inflammatory response. Cardiovasc. Res. 72: 384-393.
16. Shimamoto, A., A. J. Chong, M. Yada, S. Shomura, H. Takayama, A. J. Fleisig, M. L. Agnew, C. R. Hampton, C. L. Rothnie, D. J. Spring, et al. 2006. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 114 (Suppl. 1): 1270-1274.
17. Ha, T., Y. Li, F. Hua, J. Ma, X. Gao, J. Kelley, A. Zhao, G. E. Haddad, D. L. Williams, I. W. Browder, et al. 2005. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc. Res. 68: 224-234.
18. Baumgarten, G., P. Knuefermann, G. Schuhmacher, V. Vervolgyi, J. von Rappard, U. Dreiner, K. Fink, C. Djoufack, A. Hoeft, C. Grohe, el al. 2006. Toll-like receptor 4, nitric oxide, and myocardial depression in endoloxemia. Shock 25: 43-49.
19. Satoh, M., Y. Shimoda, C. Maesawa, T. Akatsu, Y. Ishikawa, Y. Minami, K. Hiramori, and M. Nakamura. 2006. Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int. J. Cardiol. 109: 226-234.
20. Methe, H., J. O. Kim, S. Kofler, M. Weis, M. Nabauer, and J. Koglin. 2005. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 111: 2654-2661.
21. Poltorak, A., X. He, I. Smimova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell. E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TIr4 gene. Science 282: 2085-2088.
22. Tschope, C., D. Westermann, N. Dhayat, S. Dhayat, C. Altmann, P. Steendijk, H. P. Schultheiss, and T. Walther. 2005. Angiotensin AT2 receptor deficiency after myocardial infarction: its effects on cardiac function and fibrosis depend on the stimulus. Cell Biochem. Biophys. 43: 45-52.
23. Bien, S., A. Riad, C. A. Ritter, M. Gratz, F. Olshausen, D. Westermann, M. Grube, T. Krieg, S. Ciecholewski, S. B. Felix, et al. 2007. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res. 67: 10428-10435.
24. Westermann, D., S. Rutschow, S. Jager, A. Linderer, S. Anker, A. Riad, T. Unger, H. P. Schultheiss, M. Pauschinger, and C. Tschöpe. 2007. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56: 641-646.
25. Riad, A., D. Unger, J. Du, D. Westermann, Z. Mohr, M. Sobirey, M. Dorenkamp, H. P. Schultheiss, and C. Tschope. 2007. Chronic inhibition of p38MAPK improves cardiac and endothelial function in experimental diabetes mellitus. Eur. J. Pharmacol. 554: 40-45.
26. Tschope, C., T. Walther, J. Koniger, F. Spillmann, D. Westermann, F. Escher, M. Pauschinger, J. B. Pesquero, M. Bader, H. P. Schultheiss, and M. Noutsias. 2004. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J. 18: 828-835.
27. Li, J., S. Leschka, S. Rutschow, P. L. Schwimmbeck, L. Husmann, M. Noutsias, D. Westermann, W. Poller, H. Zeichhardt, K. Klingel, et al. 2007. Immunomodu-lation by interIeukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis. Eur. J. Pharmacol. 554: 60-68.
28. T) method. Methods 25: 402-408.
29. O'Neill, L. A., and A. G. Bowie. 2007. The family of five: TIR-domain-contain-ing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7: 353-364.
30. Kang, Y. J., B. Kusler, M. Otsuka, M. Hughes, N. Suzuki, S. Suzuki, W. C. Yeh, S. Akira, J. Han, and P. P. Jones. 2007. Calcineurin negatively regulates TLR-mediated activation pathways. J. Immunol. 179: 4598-4607.
31. Sakata, Y., J. W. Dong, J. G. Vallejo, C. H. Huang, J. S. Baker, K. J. Tracey, O. Tacheuchi, S. Akira, and D. L. Mann. 2007. Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am. J. Physiol. 292: H503-H509.
32. Hua, F., T. Ha, J. Ma, Y. Li, J. Kelley, X. Gao, I. W. Browder, R. L. Kao, D. L. Williams, and C. Li. 2007. Protection against myocardial ischemia/reper-fusion injury in TLR4-deficient mice is mediated through a phosphoinositide 3-kinase-dependent mechanism. J. Immunol. 178: 7317-7324.
33. Kim, S. C., A. Ghanem, H. Stapel, K. Tiemann, P. Knuefermann, A. Hoeft, R. Meyer, C. Grohe, A. A. Knowlton, and G. Baumgarten. 2007. Toll-like receptor 4 deficiency: smaller infarcts, but no gain in function. BMC Physiol. 7: 5.
34. Stapel, H., S. C. Kim, S. Osterkamp, P. Knuefermann, A. Hoeft, R. Meyer, C. Grohe, and G. Baumgarten. 2006. Toll-like receptor 4 modulates myocardial ischaemia-reperfusion injury: role of matrix metalloproteinases. Eur. J. Heart Fail. 8: 665-672.
35. Jones, P. H., J. M. McKenney, D. G. Karalis, and J. Downey. 2005. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am. Heart J. 149: el.
36. Boekholdt, S. M., W. R. Agema, R. J. Peters, A. H. Zwinderman, E. E. van der Wall, P. H. Reitsma, J.J. Kastelein, and J. W. Jukema. 2003. Variants of Toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 107: 2416-2421.
37. Ameziane, N., T. Beillat, P. Verpillat, S. Chollet-Martin, M. C. Aumont, P. Seknadji, M. Lamotte, D. Lebret, V. Ollivier, and D. de Prost. 2003. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler. Thromb. Vasc. Biol. 23: e61-e64.
38. Tschope, C., F. Spillmann, C. Altmann. M. Koch, D. Westermann, N. Dhayat, S. Dhayat, J. L. Bascands, L. Gera, S. Hoffman, et al. 2004. The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction. Cardiovasc Res. 61: 559-569.
39. Kawai, T., and S. Akira. 2005. Toll-like receptor downstream signaling. Arthritis Res. Ther. 7: 12-19.
40. Ha, T., F. Hua, Y. Li, J. Ma, X. Gao, J. Kelley, A. Zhao, G. E. Haddad, D. L. Williams, I. W. Browder, et al. 2006. Blockade of MyD88 attenuates cardiac hypertrophy and decreases cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo. Am. J. Physiol. 290: H985-H994.
41. Fuse, K., G. Chan, Y. Liu, P. Gudgeon, M. Husain, M. Chen, W. C. Yeh, S. Akira, and P. P. Liu. 2005. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation 112: 2276-2285.
42. Hua, F., T. Ha, J. Ma, X. Gao, J. Kelley, D. L. Williams, I. W. Browder, R. L. Kao, and C. Li. 2005. Blocking the MyD88-dependent pathway protects the myocardium from ischemia/reperfusion injury in rat hearts. Biochem. Biophys. Res. Commtm. 338: 1118-1125.
43. Dong, C., R. J. Davis, and R. A. Flavell. 2002. MAP kinases in the immune response. Anna. Rev. Immunol. 20: 55-72.
44. Kubo-Murai, M., K. Hazeki, N. Sukenobu, K. Yoshikawa, K. Nigorikawa, K. Inoue, T. Yamamoto, M. Malsumoto, T. Seya, N. Inoue, and O. Hazeki. 2007. Protein kinase Cδ binds TIRAP/Mal to participate in TLR signaling. 2007. Mol. Immunol. 44: 2257-2264.
45. Biesalski, H. K., B. Bueno de Mesquita, A. Chesson, F. Chytil, R. Grimble, R. J. Hermus, J. Kohrle, R. Lotan, K. Norpoth, U. Pastorino, and D. Thumham. 1998. European consensus statement on lung cancer: risk factors and prevention: lung cancer panel. 1998. CA Cancer J. Clin. 48: 167-176.
46. Chen, L., H. Hahn, G. Wu, C. H. Chen, T. Liron, D. Schechtman, G. Cavallaro, L. Banci, Y. Guo, R. Bolli, et al. 2001. Opposing cardioprotective actions and parallel hypertrophic effects of 8 PKC and e PKC. 2001. Proc. Natl. Acad. Sci. USA 98: 11114-11119.
47. Azuma, H., M. Sugimoto-Tokushima, K. Tanaka, Y. Ikenoue, S. Ito, and M. Ishikawa. 1989. α 1-adrenoceptor antagonist activity of novel pyrimidine derivatives (SHI437 and IK29) in rabbit aorta and trigone of the bladder. Br. J. Pharmacol. 96: 1000-1006.
48. Liang, Q., and J. D. Molkentin. 2003. Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J. Mol. Cell. Cardiol. 35: 1385-1394.
49. Cantley, L. C. 2002. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
50. Hausenloy, D. J., and D. M. Yellon. 2006. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc. Res. 70: 240-253.
51. Ravingerova, T., J. Matejikova, J. Neckar, E. Andelova, and F. Kolar. 2007. Differential role of PI3K/Akt pathway in the infarct size limitation and anliar-rhythmic protection in the rat heart. Mol. Cell. Biochem. 297: 111-120.